GlassScriptPhysician profile
Faisal Akbar
NPI 1316222433
$1,260.65
in general payments reported to CMS, 2019-2025
14 companies · $242 in 2025
The $242 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $141 · 2021: $190 · 2022: $224 · 2023: $224 · 2024: $39.55 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $287 · Food and Beverage: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $286.98 |
| Food and Beverage | $218.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $289.61 | 2020-2025 | Jakafi |
| Sanofi-Aventis U.S. LLC | $134.98 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $124.98 | 2022 | |
| Pinnacle Biologics, INC | $119.08 | 2025 | Photofrin |
| Alexion Pharmaceuticals, INC. | $100.00 | 2019 | |
| Genentech USA, INC. | $99.95 | 2019 | |
| Seagen INC. | $99.95 | 2021 | |
| Janssen Biotech, INC. | $90.00 | 2021 | |
| Astellas Pharma US INC | $75.00 | 2023 | |
| Mirati Therapeutics, INC. | $42.00 | 2023 | Krazati |
| Adc Therapeutics America, INC. | $24.50 | 2024 | |
| Genzyme Corporation | $23.16 | 2025 | |
| Pfizer INC. | $22.39 | 2023 | |
| Novartis Pharmaceuticals Corporation | $15.05 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faisal Akbar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.